ISB 1442
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
What will happen during the trial?
The study will be conducted in two phases:
Phase 1: Dose escalation in R/R MM
Phase 2: Dose expansions in select R/R MM
Cohort A: R/R MM
Cohort B: R/R MM Post-T-Cell Directed Therapy Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a Recommended Phase 2 Dose (RP2D) is established in Phase 1 for a given indication, Phase 2 will be initiated for that indication.
Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 121 patients (estimated)
- Sponsors
- Ichnos Sciences SA
- Tags
- Bispecific Antibody, CD38, CD47
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1327
- NCT Identifier
- NCT05427812
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.